Ultrasound-guided injections for supraspinatus tendinopathy: corticosteroid versus glucose prolotherapy – a randomized controlled clinical trial

Background Subacromial corticosteroid injections are frequently performed for pain associated with supraspinatus tendinopathy. Glucose prolotherapy has been used clinically for multiple tendinopathies and is hypothesized to be an alternate injection therapy for supraspinatus tendinopathy. Methods A prospective, randomized, double blinded clinical trial was conducted. Thirty-six patients with supraspinatus tendinopathy were randomized into two groups: 17 received an ultrasound-guided injection of glucose into the tendinopathic parts of the supraspinatus tendon and 19 received an ultrasound-guided injection of corticosteroid into the subacromial bursa. Primary outcome was level of pain with overhead activities at 3 months. Secondary outcome measures included level and frequency of pain and function, shoulder range of motion, impingement tests, strength and tendon changes on ultrasound. Results Level of pain with overhead activities was significantly reduced at the 3-month follow-up in the prolotherapy group and at the 6-month follow-up for both the prolotherapy and corticosteroid groups. There were no significant differences between the groups at any time point. Conclusions Both glucose prolotherapy and corticosteroid were generally well tolerated; however, glucose prolotherapy offered no additional benefit over subacromial corticosteroid injection for supraspinatus tendinopathy.

Download Full-text

Su1482 THE DURABILITY OF ENDOSCOPIC ULTRASOUND-GUIDED ABLATION OF PANCREATIC CYSTS: A LONG-TERM FOLLOW-UP OF THE CHARM PROSPECTIVE, RANDOMIZED, CONTROLLED CLINICAL TRIAL

Gastroenterology ◽

10.1016/s0016-5085(20)32196-x ◽

2020 ◽

Vol 158 (6) ◽

pp. S-597

Author(s):

Courtney Lester ◽

Leonard Walsh ◽

Kayla M. Hartz ◽

Abraham Mathew ◽

John M. Levenick ◽

...

Keyword(s):

Clinical Trial ◽

Endoscopic Ultrasound ◽

Pancreatic Cysts ◽

Controlled Clinical Trial ◽

Randomized Controlled Clinical Trial ◽

Ultrasound Guided ◽

Randomized Controlled ◽

Long Term Follow Up

Download Full-text

Comparison of the effectiveness of ultrasound-guided prolotherapy in supraspinatus tendon with ultrasound-guided corticosteroid injection of subacromial subdeltoid bursa in rotator cuff-related shoulder pain: A clinical trial study

Advanced Biomedical Research ◽

10.4103/abr.abr_181_20 ◽

2021 ◽

Vol 10 (1) ◽

pp. 12

Author(s):

LeilaSadat Mohamadi Jahromi ◽

Aref Nasiri ◽

MohammadAmin Vafaei ◽

Reyhaneh Parvin ◽

MaryamSadat Fakheri ◽

...

Keyword(s):

Clinical Trial ◽

Rotator Cuff ◽

Shoulder Pain ◽

Corticosteroid Injection ◽

Supraspinatus Tendon ◽

Ultrasound Guided

Download Full-text

Comparison of efficacy of needling and a combination of needling and platelet rich plasma in relieving pain and improving function in patients of tennis elbow: a prospective, randomized, double blinded, placebo controlled clinical trial

International Journal of Research in Orthopaedics ◽

10.18203/issn.2455-4510.intjresorthop20210617 ◽

2021 ◽

Vol 7 (2) ◽

pp. 258

Author(s):

Vikram Sharma ◽

Vivek Chandak

Keyword(s):

Tennis Elbow ◽

Platelet Rich Plasma ◽

Controlled Trial ◽

Lateral Epicondylitis ◽

Secondary Outcome ◽

Controlled Clinical Trial ◽

Group A ◽

Group B ◽

Double Blinded

Background: Lateral epicondylitis is a common musculoskeletal disorder for which an effective treatment strategy remains unknown. Aim of the study was to examine whether a single injection of platelet-rich plasma (PRP) with needling is more effective than needling with placebo in reducing pain in adults with lateral epicondylitis. Study design used was randomized controlled trial. Methods: A total of 66 patients with chronic lateral epicondylitis were randomized (1:1) to receive either a blinded injection of PRP (group A) or saline (placebo) group B. The primary end point was a change in pain using the VAS and patient-rated tennis elbow evaluation (PRTEE) questionnaire. The secondary outcome being improvement in function (PRTEE scores).Results: The VAS score and PRTEE score improved significantly in both the groups at all 3 follow-up examinations. Group A had significantly better results than the group B.Conclusions: PRP injection are safe and effective management strategy for lateral epicondylitis

Download Full-text

Platelet-Rich Plasma versus Corticosteroid Intra-Articular Injections for the Treatment of Trapeziometacarpal Arthritis: A Prospective Randomized Controlled Clinical Trial

Cartilage ◽

10.1177/1947603518805230 ◽

2018 ◽

Vol 12 (1) ◽

pp. 51-61 ◽

Cited By ~ 4

Author(s):

Michael-Alexander Malahias ◽

Leonidas Roumeliotis ◽

Vasileios S. Nikolaou ◽

Efstathios Chronopoulos ◽

Ioannis Sourlas ◽

...

Keyword(s):

Clinical Trial ◽

Platelet Rich Plasma ◽

Symptomatic Relief ◽

Controlled Clinical Trial ◽

Dash Score ◽

Ultrasound Guided ◽

Radiographic Osteoarthritis ◽

Group A ◽

Group B

Various systematic reviews have recently shown that intra-articular platelet-rich plasma (IA-PRP) can lead to symptomatic relief of knee osteoarthritis for up to 12 months. There exist limited data on its use in small joints, such as the trapeziometacarpal joint (TMJ) or carpometacarpal joint (CMCJ) of the thumb. A prospective, randomized, blind, controlled, clinical trial of 33 patients with clinical and radiographic osteoarthritis of the TMJ (grades: I-III according to the Eaton and Littler classification) was conducted. Group A patients (16 patients) received 2 ultrasound-guided IA-PRP injections, while group B patients (17 patients) received 2 ultrasound-guided intra-articular methylprednisolone and lidocaine injections at a 2-week interval. Patients were evaluated prior to and at 3 and 12 months after the second injection using the visual analogue scale (VAS) 100/100, shortened Disabilities of the Arm, Shoulder, and Hand Questionnaire (Q-DASH), and patient’s subjective satisfaction. No significant differences between the baseline clinical and demographic characteristics of the 2 groups were identified. After 12 months’ follow-up, the IA-PRP treatment has yielded significantly better results in comparison with the corticosteroids, in terms of VAS score ( P = 0.015), Q-DASH score ( P = 0.025), and patients’ satisfaction ( P = 0.002). Corticosteroids offer short-term relief of symptoms, but IA-PRP might achieve a lasting effect of up to 12 months in the treatment of early to moderate symptomatic TMJ arthritis.

Download Full-text

Evaluation of the safety and efficacy of Chinese medicine in people with asymptomatic hyperuricemia: Protocol for a prospective, double-blinded, randomized, placebo controlled clinical trial.

10.21203/rs.3.rs-395566/v1 ◽

2021 ◽

Author(s):

Jing-yao Yan ◽

Ying-yan Zhou ◽

Qiao-wen Yang ◽

Jia-qi Wu ◽

Xiao-hong He

Keyword(s):

Clinical Trial ◽

Uric Acid ◽

Chinese Medicine ◽

Cardiovascular Complications ◽

Secondary Outcome ◽

Controlled Clinical Trial ◽

Therapeutic Mechanisms ◽

Double Blinded ◽

Chinese Medicine Treatment ◽

Observation Period

Abstract BackgroundHyperuricemia increases the risk of gout and cardiovascular complications. Studys show that Chinese medicine can decrease uric acid through multiple targets, but many of these studys is conducted on animal, because the lack of a consistent prescription and mechanism.So we design this research to study whether Chinese medicine is really effective and which target is essential.MethodsThis study is a prospective, double-blinded, randomized, placebo controlled clinical trial. From March 2020 to December 2021.30 asymptomatic hyperuricemia people will be recruiting and assigned to either Chinese medicine group or placebo group, each group will have 15 subjects.During the 12-week observation period,there will be 4 times of visits.The decline in the uric acid is the main outcome measure, urinary uric acid,inflammatory biomarkers and other index that may involve in lowing uric acid are the secondary outcome measures.DiscussionThis study will probe the effect of Chinese medicine treatment on hyperuricemia, and explore possible therapeutic mechanisms. By performing this trial,we hoping to provide evidence and data to support further large clinical studies.Trial registration:ChiCTR2000038575. Registered on September 24, 2020.

Download Full-text